Polymersomes as Stable Nanocarriers for a Highly Immunogenic and Durable SARS-CoV-2 Spike Protein Subunit Vaccine
暂无分享,去创建一个
F. Ginhoux | R. Dress | S. Venkataraman | M. Nallani | N. K. Mohd-Ismail | Amita Khan | Jian Hang Lam | Y. Tan | Teck Wan Chia | T. A. Cornell | D. Anderson | Kim Tien Ng | Wen Wang William Yeow
[1] C. Wiysonge,et al. COVID-19 vaccines , 2021, Current Opinion in Immunology.
[2] A. Marchant,et al. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans , 2021, Nature Reviews Immunology.
[3] M. Davenport,et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[4] Haiguang Liu,et al. Harnessing peak transmission around symptom onset for non-pharmaceutical intervention and containment of the COVID-19 pandemic , 2021, Nature Communications.
[5] Swapnil Mahajan,et al. Immunodominant T-cell epitopes from the SARS-CoV-2 spike antigen reveal robust pre-existing T-cell immunity in unexposed individuals , 2020, Scientific Reports.
[6] M. Nussenzweig,et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies , 2020, Nature.
[7] F. Ginhoux,et al. Genetic models of human and mouse dendritic cell development and function , 2020, Nature reviews. Immunology.
[8] H. Brüssow. Faculty Opinions recommendation of SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[9] Ralf Bartenschlager,et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions , 2020, Nature.
[10] R. Coffman,et al. Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19 , 2020, Scientific Reports.
[11] Martin Linster,et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.
[12] Chul-Joong Kim,et al. Neutralizing Antibody Production in Asymptomatic and Mild COVID-19 Patients, in Comparison with Pneumonic COVID-19 Patients , 2020, Journal of clinical medicine.
[13] Morten Nielsen,et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.
[14] Qiang Zhou,et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 , 2020, Science.
[15] X. Tang,et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections , 2020, Nature Medicine.
[16] D. Burton,et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.
[17] Yuan Wang,et al. Identifying airborne transmission as the dominant route for the spread of COVID-19 , 2020, Proceedings of the National Academy of Sciences.
[18] J. Mascola,et al. SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness , 2020, bioRxiv.
[19] C. Poh,et al. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients , 2020, Nature Communications.
[20] Marc C. Johnson,et al. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein , 2020, Journal of Virology.
[21] J. Greenbaum,et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.
[22] H. Achdout,et al. Tiger team: a panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes , 2020, bioRxiv.
[23] M. V. van Breemen,et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.
[24] H. Yen,et al. Peer Review File Manuscript Title: Pathogenesis and transmission of SARS-CoV-2 in golden Syrian hamsters , 2020 .
[25] J. Leroux,et al. Twenty-five years of polymersomes: lost in translation? , 2020, Materials Horizons.
[26] Barney S. Graham,et al. Rapid COVID-19 vaccine development , 2020, Science.
[27] Yusen Duan,et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals , 2020, Nature.
[28] M. Koopmans,et al. SARS-CoV-2 is transmitted via contact and via the air between ferrets , 2020, bioRxiv.
[29] C. Hillyer,et al. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses , 2020, Trends in Immunology.
[30] B. Liedberg,et al. Facile Mixing of Phospholipids Promotes Self-Assembly of Low-Molecular-Weight Biodegradable Block Co-Polymers into Functional Vesicular Architectures , 2020, Polymers.
[31] Yan Liu,et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV , 2020, Nature Communications.
[32] A. Walls,et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.
[33] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[34] A. M. Leontovich,et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 , 2020, Nature Microbiology.
[35] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.
[36] M. Blenner,et al. Polymersomes for therapeutic delivery of protein and nucleic acid macromolecules: From design to therapeutic applications. , 2020, Biomacromolecules.
[37] Yuanyu Huang,et al. The challenge and prospect of mRNA therapeutics landscape. , 2020, Biotechnology advances.
[38] J. Nie,et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2 , 2020, Emerging microbes & infections.
[39] Petra Schwille,et al. Liposomes and polymersomes: a comparative review towards cell mimicking. , 2018, Chemical Society reviews.
[40] X. Tao,et al. A CpG oligodeoxynucleotide enhances the immune response to rabies vaccination in mice , 2018, Virology Journal.
[41] Jianbo Jia,et al. Interactions Between Nanoparticles and Dendritic Cells: From the Perspective of Cancer Immunotherapy , 2018, Front. Oncol..
[42] Yanbo Ma,et al. Nanotoxicity of Silver Nanoparticles on HEK293T Cells: A Combined Study Using Biomechanical and Biological Techniques , 2018, ACS omega.
[43] F. Ginhoux,et al. Homeostatic control of dendritic cell numbers and differentiation , 2018, Immunology and cell biology.
[44] Han‐Gon Choi,et al. Optimization and physicochemical characterization of a cationic lipid-phosphatidylcholine mixed emulsion formulated as a highly efficient vehicle that facilitates adenoviral gene transfer , 2017, International journal of nanomedicine.
[45] M. Bachmann,et al. Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination , 2017, Journal of controlled release : official journal of the Controlled Release Society.
[46] C. Weyand,et al. The life cycle of a T cell after vaccination – where does immune ageing strike? , 2017, Clinical and experimental immunology.
[47] D. Meyerholz,et al. RSV Vaccine-Enhanced Disease Is Orchestrated by the Combined Actions of Distinct CD4 T Cell Subsets , 2015, PLoS pathogens.
[48] T. Lawrence,et al. Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming , 2014, The EMBO journal.
[49] J. Hubbell,et al. Tunable T cell immunity towards a protein antigen using polymersomes vs. solid-core nanoparticles. , 2013, Biomaterials.
[50] D. W. Pack,et al. Design of hybrid lipid/retroviral-like particle gene delivery vectors. , 2013, Molecular pharmaceutics.
[51] K. Steinbrink,et al. Costimulatory Molecules on Immunogenic Versus Tolerogenic Human Dendritic Cells , 2013, Front. Immunol..
[52] Miriam Merad,et al. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. , 2013, Annual review of immunology.
[53] J. Hubbell,et al. Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes. , 2012, Biomaterials.
[54] S. Mittal,et al. Adenoviral vector immunity: its implications and circumvention strategies. , 2011, Current gene therapy.
[55] Wah Chiu,et al. Interbilayer-Crosslinked Multilamellar Vesicles as Synthetic Vaccines for Potent Humoral and Cellular Immune Responses , 2011, Nature materials.
[56] E. Clark,et al. The role of CD40 and CD154/CD40L in dendritic cells. , 2009, Seminars in immunology.
[57] A. Halperin. Polymeric vs. Monomeric Amphiphiles: Design Parameters , 2006 .
[58] W. Hong,et al. Monoclonal Antibodies Targeting the HR2 Domain and the Region Immediately Upstream of the HR2 of the S Protein Neutralize In Vitro Infection of Severe Acute Respiratory Syndrome Coronavirus , 2006, Journal of Virology.
[59] A. Iwasaki,et al. Toll-like receptor control of the adaptive immune responses , 2004, Nature Immunology.
[60] Praveen Elamanchili,et al. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery. , 2004, Current drug delivery.
[61] H. Davis,et al. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. , 2001, FEMS immunology and medical microbiology.
[62] R. Kammerer,et al. Stabilization of short collagen-like triple helices by protein engineering. , 2001, Journal of molecular biology.
[63] D. Hammer,et al. Polymersomes: tough vesicles made from diblock copolymers. , 1999, Science.
[64] H. Six,et al. Immunoglobulin G subclass antibody responses of mice to influenza virus antigens given in different forms. , 1987, Antiviral research.
[65] J. Snick,et al. IgG2a restriction of murine antibodies elicited by viral infections , 1987, The Journal of experimental medicine.
[66] R. Chanock,et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. , 1969, American journal of epidemiology.
[67] J. Luban. SARS-CoV-2 , 2020 .
[68] J. Pallesen,et al. Prefusion coronavirus spike proteins and their use , 2017 .
[69] V. Fulginiti,et al. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. , 1967, JAMA.